Sessions

Future-Proofing Cell Therapy Production
Technology, Disruptive Innovation and Partnerships that are Revolutionizing How Medicines Are Made
Overcoming Scale Up Process Development Challenges for Pluripotent Stem Cell Derived Therapies
Add It Up: 3 Things to Consider for Capacity Expansion
Unlocking the Potential of Advanced Therapies Through Collaborations
Why So Shy? Implementing Disruptive Technologies with Confidence in Cell Therapy

Future-Proofing Cell Therapy Production

26 Jan 2022
12:30
Briefing Room
SPONSORED BY
ScaleReady

This Session will:

  • Define essential attributes to future-proof manufacturing.
  • Discuss current industry strategies pursuing sustainable, flexible, and scalable processes.
  • Explore the necessity and challenges of process standardization within the industry.
  • Evaluate possibility of a platform that future-proofs both autologous and allogeneic therapies

Moderator: 
Josh Ludwig, Global Director of Commercial Operations, ScaleReady

Panellists:

Mamta Kalra, Director CMC, Immatics

Matthew Li, Associate Director, Head of Cell Therapy Manufacturing Innovation, Vor Biopharma

Greta Garrido, Principal Scientist, NxACT, Nurix Therapeutics

Speakers

Josh Ludwig
Global Director, Commercial Operations
ScaleReady
Mamta Kalra
Director, Department of Chemistry, Manufacture and Control (CMC)
Immatics
Matthew Li
Associate Director, Head of Cell Therapy Manufacturing Innovation
Vor Biopharma